Trending

Jazz Pharmaceuticals

Harmony’s sleep disorder drug Wakix gets US label extension

Harmony’s sleep disorder drug Wakix gets US label extension

Harmony Biosciences has scored an expanded use for its Wakix narcolepsy drug to include cataplexy – a symptom

X

Harmony’s sleep disorder drug Wakix gets US label extension

https://pharmaphorum.com/news/harmonys-narcolepsy-drug-gets-extended-cataplexy/

FDA approves Jazz Pharmaceuticals’ narcolepsy therapy

FDA approves Jazz Pharmaceuticals’ narcolepsy therapy

The FDA has approved Jazz Pharmaceuticals’ sleep disorder drug Xywav, to treat daytime sleepiness in patients with narcolepsy,

X

FDA approves Jazz Pharmaceuticals’ narcolepsy therapy

https://pharmaphorum.com/news/fda-approves-jazz-pharmaceuticals-narcolepsy-therapy/

Jazz targets US launch of SCLC drug after FDA grants fast review

Jazz targets US launch of SCLC drug after FDA grants fast review

PharmaMar and Jazz Pharmaceuticals have announced the FDA has granted a six-month Priority Review for their lurbinectedin for

X

Jazz targets US launch of SCLC drug after FDA grants fast review

https://pharmaphorum.com/news/jazz-targets-us-launch-of-sclc-drug-after-fda-grants-fast-review/

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

Spain’s PharmaMar and Jazz Pharmaceuticals have signed a $1 billion license agreement for the lung cancer drug lurbinectedin

X

PharmaMar and Jazz sign $1bn US deal for lung cancer drug lurbinectedin

https://pharmaphorum.com/news/pharmamar-and-jazz-sign-1bn-us-deal-for-lung-cancer-drug/

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

The EMA’s human medicines advisory committee recommended approval of five novel medicines at its November meeting, including Novartis’

X

Novartis’ Mayzent, Roche’s Polivy head latest crop of CHMP approvals

https://pharmaphorum.com/news/novartis-mayzent-roches-polivy-head-latest-crop-of-chmp-approvals/

Priority review voucher prices fall again after Spark’s $110m sale

Priority review voucher prices fall again after Spark’s $110m sale

Voucher prices have fallen since their 2015 peak

X

Priority review voucher prices fall again after Spark’s $110m sale

https://pharmaphorum.com/news/spark-sells-priority-review-voucher-to-jazz/

EUSA Pharma looks to further in-licensing to build growth

EUSA Pharma looks to further in-licensing to build growth

Specialist company EUSA Pharma is looking for new medicines to develop after getting two cancer drugs recommended by European

X

EUSA Pharma looks to further in-licensing to build growth

https://pharmaphorum.com/news/uks-eusa-pharma-looks-bolster-pipeline/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com